Search
Now showing items 1-5 of 5
Proyecto arRISKu MUGAN: materiales para la reducción de los riesgos asociados al consumo de drogas
(Revista de la Asociación Española de Neuropsiquiatría, 2014)
[ES]Introducción: El Proyecto “arRISKu MUGAN” ha sido diseñado por las autoras en 2010, desde el Servicio de Psicología Aplicada de la UPV/EHU, con el apoyo de la Dirección de Drogodepen-dencias del Gobierno Vasco, la ...
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
(Sage, 2014-05-22)
Background: Natalizumab has shown its efficacy in reducing multiple sclerosis (MS) relapses and progression of disability; however, it has been associated with an increased risk of developing progressive multifocal ...
Sustained increase of PKA activity in the post-commissural putamen of dyskinetic monkeys
(2014)
Levodopa-induced dyskinesias (LID) are a frequent complication of Parkinson's disease pharmacotherapy that causes significant disability and narrows the therapeutic window. Pharmacological management of LID is challenging ...
Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression
(Public Library Science, 2014-02-28)
Background: Although the most common clinical presentation of multiple sclerosis (MS) is the so called Relapsing-Remitting MS (RRMS), the molecular mechanisms responsible for its progression are currently unknown. To tackle ...
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats
(Elsevier, 2014-04)
Dopamine replacement with l-DOPA is the most effective therapy in Parkinson's disease. However, with chronic treatment, half of the patients develop an abnormal motor response including dyskinesias. The specific molecular ...